{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T14:16:30Z","timestamp":1768313790786,"version":"3.49.0"},"reference-count":7,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.msard.2022.103492","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T21:18:24Z","timestamp":1641935904000},"page":"103492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate"],"prefix":"10.1016","volume":"58","author":[{"given":"Callum H","family":"Wood","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil P","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zin Min","family":"Htet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma C","family":"Tallantyre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2022.103492_bib0005","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419843450","article-title":"Time course of lymphocyte repopulation after dimethyl fumarate-induced grade 3 lymphopenia: contribution of patient age","author":"Briner","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.msard.2022.103492_bib0003","unstructured":"Coles A., Lim A., Giovannoni G., et\u00a0al., 2020. ABN guidance on the use of disease-modifying therapies in multiple sclerosis in response to the COVID-19 pandemic. https:\/\/cdn.ymaws.com\/www.theabn.org\/resource\/collection\/65C334C7-30FA-45DB-93AA-74B3A3A20293\/ABN_Guidance_on_DMTs_for_MS_and_COVID_19_VERSION_18_May_FINAL.pdf (accessed 7 July 2021)."},{"key":"10.1016\/j.msard.2022.103492_bib0002","unstructured":"European Medicines Agency, 2020. Tecfidera, dimethyl fumurate \u2013 summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tecfidera-epar-product-information_en.pdf (2020 (accessed 7 July 2021)."},{"issue":"3","key":"10.1016\/j.msard.2022.103492_bib0001","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1212\/CPJ.0000000000000238","article-title":"Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: patient management considerations","volume":"6","author":"Fox","year":"2016","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.msard.2022.103492_bib0007","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1007\/s00415-021-10412-0","article-title":"Predictors of lymphocyte count recovery after dimethyl fumarate\u2011induced lymphopenia in people with multiple sclerosis","volume":"268","author":"Lucchini","year":"2021","journal-title":"J Neurol"},{"issue":"132","key":"10.1016\/j.msard.2022.103492_bib0004","article-title":"Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate","volume":"267","author":"Morales","year":"2020","journal-title":"J Neurol"},{"issue":"8","key":"10.1016\/j.msard.2022.103492_bib0006","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1007\/s00415-020-09848-7","article-title":"Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population","volume":"267","author":"Sabin","year":"2020","journal-title":"J Neurol"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822000074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822000074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:04:00Z","timestamp":1761901440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822000074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":7,"alternative-id":["S2211034822000074"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.103492","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.103492","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2022 Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103492"}}